

# Philipp Ivanyi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3766192/publications.pdf>

Version: 2024-02-01

179  
papers

3,001  
citations

186265

28  
h-index

214800

47  
g-index

198  
all docs

198  
docs citations

198  
times ranked

2557  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Prospectively Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study). <i>Oncology Research and Treatment</i> , 2022, 45, 272-280.	1.2	0
2	cMET: a prognostic marker in papillary renal cell carcinoma?. <i>Human Pathology</i> , 2022, 121, 1-10.	2.0	3
3	Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort. <i>Journal of Cancer</i> , 2022, 13, 1706-1712.	2.5	5
4	Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma after Prior Therapy: Interim Results from the Noninterventional NORA Study. <i>European Urology Focus</i> , 2022, 8, 1289-1299.	3.1	4
5	The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma. <i>Urologia Internationalis</i> , 2022, 106, 1168-1176.	1.3	3
6	Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 53-59.e1.	1.9	6
7	Prognostic role of docetaxel-induced reduction of free testosterone serum levels in metastatic prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 144-144.	1.6	0
8	Role of free testosterone serum levels during salvage chemotherapy with carboplatin plus weekly docetaxel in patients with docetaxel-refractory, metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 145-145.	1.6	0
9	Checkpoint inhibitorâ€‘induced autoimmune central nervous system disorder in patients with metastatic melanoma and Hodgkinâ€™s lymphoma. <i>Clinical and Experimental Neuroimmunology</i> , 2021, 12, 127-134.	1.0	1
10	Protective measures for patients with advanced cancer during the Sars-CoV-2 pandemic: Quo vadis?. <i>Clinical and Experimental Metastasis</i> , 2021, 38, 257-261.	3.3	6
11	Impact of sarcopenia in advanced and metastatic soft tissue sarcoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2151-2160.	2.2	13
12	Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients. <i>Scientific Reports</i> , 2021, 11, 16457.	3.3	1
13	1550P A post hoc analysis of the EPAZ trial: The prognostic role of geriatric variables in elderly soft tissue sarcoma (STS) patients. <i>Annals of Oncology</i> , 2021, 32, S1125-S1126.	1.2	0
14	912P Results of a randomized phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) (ELDORANDO-AIO-KHT-0115). <i>Annals of Oncology</i> , 2021, 32, S807-S808.	1.2	2
15	679P Final results on efficacy and patient reported outcomes (PRO) of a randomized phase II trial investigating nivolumab switch-maintenance after TKI induction in metastatic clear cell renal cell carcinoma (mRCC) patients (NIVOSWITCH). <i>Annals of Oncology</i> , 2021, 32, S700.	1.2	0
16	Prognostic Impact of Lymphnode Metastases in Patients with Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2021,, 1-8.	0.4	0
17	Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma. <i>Future Oncology</i> , 2020, 16, 2307-2328.	2.4	17
18	Extracorporeal portosystemic shunt in secondary Budd-Chiari syndrome. <i>Journal of Hepatology</i> , 2020, 73, 974-976.	3.7	1

#	ARTICLE	IF	CITATIONS
19	Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 3555-3564.	1.6	56
20	Systemic treatment of advanced/metastatic renal cell carcinoma in the context of SARS-CoV-2 pandemic: recommendations from the interdisciplinary working group for renal tumors (IAG-N). <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3075-3078.	2.5	4
21	Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy. <i>Journal of Oncology</i> , 2020, 2020, 1-9.	1.3	6
22	642P Role of free testosterone serum levels during salvage chemotherapy with carboplatin plus weekly docetaxel in patients with docetaxel-refractory, metastatic castration-resistant prostate cancer (mCRPC). <i>Annals of Oncology</i> , 2020, 31, S527.	1.2	0
23	666P Prognostic role of docetaxel-induced reduction of free testosterone serum levels in metastatic prostate cancer patients. <i>Annals of Oncology</i> , 2020, 31, S537.	1.2	0
24	Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy – Real-World Clinical Impressions and Comparative Review of the Literature. <i>Frontiers in Oncology</i> , 2020, 10, 808.	2.8	11
25	Lower-dosing ponatinib in pre-treated GIST: Results of the POETIG phase II trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11536-11536.	1.6	3
26	A randomized phase II trial comparing switch to nivolumab with TKI continuation after 12 weeks of TKI induction therapy in metastatic renal cell carcinoma patients (NIVOSWITCH).. <i>Journal of Clinical Oncology</i> , 2020, 38, 678-678.	1.6	2
27	Hepatic toxicity during regorafenib treatment in patients with metastatic gastrointestinal stromal tumors. <i>Molecular and Clinical Oncology</i> , 2020, 13, 1-1.	1.0	7
28	A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS5103-TPS5103.	1.6	6
29	Which patients with pre-treated locally advanced or metastatic sarcoma benefit most from trabectedin treatment: First results of a retrospective study of the German Interdisciplinary Sarcoma Group (GISG-14 - ReTraSarc).. <i>Journal of Clinical Oncology</i> , 2020, 38, 11554-11554.	1.6	0
30	Survival in metastatic renal cell carcinoma (mRCC) patients over two decades: Does age matter?. <i>Journal of Clinical Oncology</i> , 2020, 38, e17103-e17103.	1.6	0
31	A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH). <i>Annals of Oncology</i> , 2019, 30, v388.	1.2	0
32	A randomized phase II study on the OPTimization of Immunotherapy in squamous carcinoma of the head and neck (SCCHN) - OPTIM (AIO-KHT-0117). <i>Annals of Oncology</i> , 2019, 30, v474.	1.2	0
33	Soft tissue sarcomas express a distinct mRNA immune profile. <i>Annals of Oncology</i> , 2019, 30, v702.	1.2	0
34	Renal cell carcinoma in kidney transplant recipients: descriptive analysis and overview of a major German transplant center. <i>Future Oncology</i> , 2019, 15, 3739-3750.	2.4	5
35	Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy – Review of the Literature and Future Outlook. <i>Journal of Clinical Medicine</i> , 2019, 8, 1777.	2.4	87
36	Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 714-726.	3.9	49

#	ARTICLE	IF	CITATIONS
37	Sarcoid-Like Lesions Mimicking Pulmonary Metastasis: A Case Series and Review of the Literature. <i>Oncology Research and Treatment</i> , 2019, 42, 382-386.	1.2	1
38	Piwi-like 1 protein expression is a prognostic factor for renal cell carcinoma patients. <i>Scientific Reports</i> , 2019, 9, 1741.	3.3	11
39	Bevacizumab-associated glomerular microangiopathy. <i>Modern Pathology</i> , 2019, 32, 684-700.	5.5	37
40	A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-STS 0415).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS11075-TPS11075.	1.6	2
41	Sarcopenia (SMI(+)) in patients (pts) with advanced or metastatic soft tissue sarcoma (a/mSTS): Potential parameter for risk prediction during multimodal therapy (MT)?. <i>Journal of Clinical Oncology</i> , 2019, 37, 11069-11069.	1.6	0
42	Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab. <i>European Journal of Cancer</i> , 2018, 93, 150-153.	2.8	43
43	Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC). <i>Annals of Oncology</i> , 2018, 29, viii294.	1.2	0
44	Metastatic Liposarcoma: A Case of Partial Remission with Eribulin in Late Treatment Lines. <i>Journal of Clinical Case Reports</i> , 2018, 08, .	0.0	0
45	Active surveillance and deferred medical treatment (ASDT) in metastatic renal cell carcinoma (mRCC): Update of a single center experience and efficacy of medical treatment.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4581-4581.	1.6	0
46	Prognostic value of testosterone levels during chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, e17069-e17069.	1.6	0
47	Association of multimodality treatment (MT) with improved overall survival (OS) in patients (pts) with advanced/metastatic soft tissue sarcoma (a/m STS).. <i>Journal of Clinical Oncology</i> , 2018, 36, e23566-e23566.	1.6	0
48	Prognostic impact of PD-1 and its ligands in renal cell carcinoma. <i>Medical Oncology</i> , 2017, 34, 99.	2.5	19
49	CT patterns of organizing pneumonia in patients treated with VEGF/mTOR inhibitors for metastatic renal cell cancer: an observational study. <i>Acta Radiologica Open</i> , 2017, 6, 205846011769421.	0.6	2
50	PD-L2: A prognostic marker in chromophobe renal cell carcinoma?. <i>Medical Oncology</i> , 2017, 34, 71.	2.5	17
51	c-Met in chromophobe renal cell carcinoma. <i>Medical Oncology</i> , 2017, 34, 15.	2.5	8
52	Impact of alpha 1-antitrypsin deficiency and prior augmentation therapy on patients' survival after lung transplantation. <i>European Respiratory Journal</i> , 2017, 50, 1700962.	6.7	10
53	Therapy of Treatment-Related Hypertension in Metastatic Renal-Cell Cancer Patients Receiving Sunitinib. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 280-290.e3.	1.9	6
54	Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis. <i>Journal of Kidney Cancer and VHL</i> , 2017, 4, 8-15.	1.0	7

#	ARTICLE	IF	CITATIONS
55	Prognostic value of free testosterone (FT) levels during chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. Journal of Clinical Oncology, 2017, 35, 5039-5039.	1.6	0
56	Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?. World Journal of Urology, 2016, 34, 909-915.	2.2	5
57	Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?. Medical Oncology, 2016, 33, 59.	2.5	22
58	PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?. Medical Oncology, 2016, 33, 120.	2.5	23
59	Impact of a salvage chemotherapy with carboplatin plus docetaxel on testosterone levels in metastatic castration - and docetaxel-resistant prostate cancer (mDRPC). Annals of Oncology, 2016, 27, vi541.	1.2	0
60	Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). Medical Oncology, 2016, 33, 80.	2.5	32
61	Prognostic significance of free testosterone levels during chemotherapy with carboplatin plus docetaxel (CD) in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. Journal of Clinical Oncology, 2016, 34, 5029-5029.	1.6	1
62	Active surveillance (AS) in the management of patients (pts) with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2016, 34, e16070-e16070.	1.6	1
63	TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO). Annals of Oncology, 2015, 26, 561-567.	1.2	55
64	Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres. Medical Oncology, 2014, 31, 147.	2.5	10
65	High cut-off dialysis as a salvage therapy option in high-dose methotrexate chemotherapy?. Annals of Hematology, 2014, 93, 1053-1055.	1.8	5
66	Late onset of bone metastases as a prognostic parameter in metastatic renal cell cancer (mRCC): A single-center experience in 82 mRCC patients treated with sunitinib.. Journal of Clinical Oncology, 2014, 32, 523-523.	1.6	0
67	Salvage chemotherapy with carboplatin plus weekly docetaxel in patients (pts) with castration- and docetaxel-resistant prostate cancer (DRPC): Associations of patient and disease characteristics with overall survival (OS).. Journal of Clinical Oncology, 2014, 32, 75-75.	1.6	0
68	Confusion of Therapeutic Approaches. Deutsches A&#x0308;rztblatt International, 2014, 111, 405.	0.9	0
69	Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. Journal of Clinical Oncology, 2014, 32, 5084-5084.	1.6	0
70	Phenotyping Established Chronic Lung Allograft Dysfunction Predicts Extracorporeal Photopheresis Response in Lung Transplant Patients. American Journal of Transplantation, 2013, 13, 911-918.	4.7	90
71	Reconstitution and Phenotype of Tregs in CMV Reactivating Patients Following Allogeneic Hematopoietic Stem Cell Transplantation. Immunological Investigations, 2013, 42, 18-35.	2.0	16
72	Interstitial lung diseases during treatment with sunitinib or mTOR inhibitors in metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 420-420.	1.6	13

#	ARTICLE	IF	CITATIONS
73	Human Regulatory T Cells of G-CSF Mobilized Allogeneic Stem Cell Donors Qualify for Clinical Application. PLoS ONE, 2012, 7, e51644.	2.5	24
74	Temsirolimus Is Active in Refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) Failing Platinum-Based Chemotherapy and Cetuximab: Efficacy and Toxicity Data from the Phase II Temhead Study. Annals of Oncology, 2012, 23, ix336-ix337.	1.2	4
75	7053 POSTER Hormonal Impact of Second-line Salvage Chemotherapy With Carboplatin Plus Weekly Docetaxel in Patients With Castration and Docetaxel-resistant Prostate Cancer. European Journal of Cancer, 2011, 47, S501.	2.8	0
76	Isolation strategies of regulatory T cells for clinical trials: Phenotype, function, stability, and expansion capacity. Experimental Hematology, 2011, 39, 1152-1160.	0.4	50
77	Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients. World Journal of Urology, 2011, 29, 355-360.	2.2	9
78	Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (DRPC).. Journal of Clinical Oncology, 2011, 29, 172-172.	1.6	0
79	Impact of carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (DRPC) on free testosterone levels.. Journal of Clinical Oncology, 2011, 29, 4593-4593.	1.6	0
80	Regulatory T Cells of G-CSF Mobilized Stem Cell Donors Qualify for Clinical Applications,. Blood, 2011, 118, 4055-4055.	1.4	0
81	Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer. World Journal of Urology, 2010, 28, 391-398.	2.2	18
82	Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients. World Journal of Urology, 2010, 28, 311-317.	2.2	2
83	Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. BMC Cancer, 2010, 10, 695.	2.6	63
84	Self-Expanding Metallic Stent Placement with Laryngeal Mask in Lung Transplant Recipients. Transplantation Proceedings, 2010, 42, 4595-4599.	0.6	4
85	Carboplatin plus weekly docetaxel as second-line chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2010, 28, 4682-4682.	1.6	1
86	Pre T-cell receptor alpha (pTalpha) expression patterns and functional analysis in human T-cell lymphoblastic leukemia. Cellular Oncology, 2010, 32, 101-8.	1.9	1
87	Molecular Targeted Therapies for Solid Tumors: Management of Side Effects. Oncology Research and Treatment, 2009, 32, 129-138.	1.2	15
88	7150 Response of renal lesions in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib – a single center retrospective analysis. European Journal of Cancer, Supplement, 2009, 7, 438.	2.2	0
89	High response to docetaxel (D)/carboplatin (C) based chemotherapy as salvage therapy in patients with docetaxel-resistant metastatic hormone-refractory prostate cancer (HRPC). Journal of Clinical Oncology, 2009, 27, e16041-e16041.	1.6	0
90	Association of therapy with sunitinib and treatment-related hyperparathyroidism in renal cell carcinoma. Journal of Clinical Oncology, 2009, 27, e16023-e16023.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Novel Therapies in Advanced Renal Cell Carcinoma. Deutsches A&#x0308;rztblatt International, 2008, 105, 232-7.	0.9	22
92	Outcome of second-line chemotherapy with a combination of docetaxel and carboplatin (DC) in docetaxel-resistant (DR) hormone refractory prostate cancer (HRPC) patients. Journal of Clinical Oncology, 2008, 26, 16090-16090.	1.6	0
93	Comparison of amino acid compositions of peptides eluted from HLA-B27 molecules of healthy individuals and patients with ankylosing spondylitis. Immunology Letters, 2006, 103, 135-141.	2.5	12
94	PROLONGED SURVIVAL OF MATERNAL SKIN GRAFTS IN NEWBORN RABBITS. Annals of the New York Academy of Sciences, 2006, 129, 234-240.	3.8	3
95	Identification of novel regulators in T-cell differentiation of aplastic anemia patients. BMC Genomics, 2006, 7, 263.	2.8	15
96	Sexual dimorphism, but not testosterone itself, is responsible for ankylosing enthesitis of the ankle in B10.BR (H-2k) male mice. Annals of the Rheumatic Diseases, 2006, 65, 130-132.	0.9	7
97	Antigen-recognition sites of micromanipulated T cells in patients with acquired aplastic anemia. Experimental Hematology, 2005, 33, 804-810.	0.4	4
98	Inflammatory pseudotumor of the lung following invasive aspergillosis in a patient with chronic graft-vs.-host disease. European Journal of Haematology, 2005, 75, 68-72.	2.2	23
99	Regulation of T Cell Homeostasis and Cell Cycling in Patients with Acute Myeloid Leukemia.. Blood, 2005, 106, 2767-2767.	1.4	0
100	Germ-free mice do not develop ankylosing enthesopathy, a spontaneous joint disease. Human Immunology, 2000, 61, 555-558.	2.4	68
101	Strong association of HLA-B27 heavy chain with $\beta$ 2-microglobulin. Human Immunology, 2000, 61, 1197-1201.	2.4	9
102	Histopathology of Murine Ankylosing Entesopathy. Pathology Research and Practice, 1998, 194, 797-803.	2.3	26
103	Solitary Caging Protects Mice from Ankylosing Entesopathy. Clinical Rheumatology, 1996, 15, 32-33.	2.2	5
104	Grouped caging predisposes male mice to ankylosing entesopathy.. Annals of the Rheumatic Diseases, 1996, 55, 645-647.	0.9	21
105	Maternal age influences risk for HLA-B27 associated ankylosing entesopathy in transgenic mice.. Annals of the Rheumatic Diseases, 1995, 54, 754-756.	0.9	14
106	Estimates of cytotoxic T-lymphocyte precursor frequencies against HLA class I antigens in responder-stimulator pairs with a negative mixed lymphocyte culture reaction. Human Immunology, 1995, 44, 97-102.	2.4	1
107	Self-restricted primary human histocompatibility leukocyte antigen (HLA)-specific cytotoxic T lymphocytes. International Immunology, 1993, 5, 103-107.	4.0	14
108	Immunogenetics of the spondyloarthropathies. Current Opinion in Rheumatology, 1993, 5, 436-445.	4.3	14

#	ARTICLE	IF	CITATIONS
109	Absence of autoantibodies to peptides shared by HLA-B27.5 and <i>Klebsiella pneumoniae</i> nitrogenase in serum samples from HLA-B27 positive patients with ankylosing spondylitis and Reiter's syndrome.. <i>Annals of the Rheumatic Diseases</i> , 1992, 51, 783-789.	0.9	27
110	H-2 influence on ankylosing enthesopathy of the ankle (ANKENT). <i>Folia Biologica</i> , 1992, 38, 258-62.	0.6	5
111	A subpopulation of mouse cytotoxic T lymphocytes recognizes allogeneic H-2 class I antigens in the context of other H-2 class I molecules.. <i>Journal of Experimental Medicine</i> , 1991, 174, 15-19.	8.5	26
112	FREQUENCY ANALYSIS OF HLA-SPECIFIC CYTOTOXIC T LYMPHOCYTE PRECURSORS IN HUMANS. Transplantation, 1991, 51, 1096-1103.	1.0	19
113	Dysfunction of HLA-B27. <i>Scandinavian Journal of Rheumatology</i> , 1990, 19, 51-69.	1.1	13
114	Variations in the T-cell repertoire against HLA antigens in humans. <i>Human Immunology</i> , 1990, 27, 1-15.	2.4	16
115	Specificity and frequency of primary anti-HLA cytotoxic T lymphocytes in normal and HLA-B27.2-, HLA-B27.5-, and HLA-Cw3-transgenic mice. A transgenic model for MHC xenoantigen recognition. <i>Journal of Immunology</i> , 1990, 144, 4513-9.	0.8	10
116	HLA expression and function in single and double HLA-B27-transgenic mice. <i>Tissue Antigens</i> , 1989, 34, 50-63.	1.0	15
117	Immunization with syngeneic Sendai virus-infected cells induce no MHC-restricted antibodies but antibodies specific for H-2 class I determinants. <i>Immunogenetics</i> , 1989, 29, 108-111.	2.4	4
118	Recognition of xeno-(HLA, SLA) major histocompatibility complex antigens by mouse cytotoxic T cells is not H-2 restricted: a study with transgenic mice.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989, 86, 617-620.	7.1	35
119	Individual Differences Among Syngeneic Mice in Immune Response to Alloantigens and Modified Self-MHC-Antigens. , 1989, , 122-133.		0
120	Different linkage disequilibria of HLA-B27 subtypes and HLA-C locus alleles. <i>Tissue Antigens</i> , 1988, 32, 74-77.	1.0	12
121	Naturally Occurring H-2 Specific Antibodies. , 1988, , 7-13.		0
122	Distribution of HLA-B27 subtypes in patients with ankylosing spondylitis: the disease is associated with a common determinant of the various B27 molecules.. <i>Annals of the Rheumatic Diseases</i> , 1987, 46, 353-356.	0.9	99
123	Conventional alloantisera can recognize the same HLA-B27 polymorphism as detected by cytotoxic T lymphocytes. <i>Human Immunology</i> , 1987, 20, 265-271.	2.4	16
124	Induction of H-2-specific antibodies by injections of syngeneic Sendai virus-coated cells. <i>European Journal of Immunology</i> , 1987, 17, 27-35.	2.9	28
125	HLA-restricted recognition of viral antigens in HLA transgenic mice. <i>Nature</i> , 1987, 329, 447-449.	27.8	84
126	Fine specificity of human HLA-B7-specific cytotoxic T-lymphocyte clones. I. Identification of HLA-B7 subtypes and histotopes of the HLA-B7 cross-reacting group. <i>Human Immunology</i> , 1986, 16, 375-389.	2.4	23



#	ARTICLE	IF	CITATIONS
127	An improved biochemical method for the analysis of HLA-class I antigens. Definition of new HLA-class I subtypes. Human Immunology, 1986, 16, 169-181.	2.4	168
128	Blind confirmation in Leiden of Geczy factor on the cells of Dutch patients with ankylosing spondylitis. Human Immunology, 1986, 17, 239-245.	2.4	19
129	Identification of new B27 subtypes (B27C and B27D) prevalent in oriental populations. Human Immunology, 1986, 16, 163-168.	2.4	47
130	Evidence for a regulatory role of the T8 (CD8) antigen in antigen-specific and anti-T3-(CD3)-induced lytic activity of allospecific cytotoxic T lymphocyte clones. European Journal of Immunology, 1986, 16, 1363-1371.	2.9	34
131	Polymorphic and autoreactive H-2-specific monoclonal antibody isolated after injections of syngeneic sendai virus-coated lymphocytes. Immunogenetics, 1986, 24, 402-408.	2.4	13
132	ANTI-MHC IMMUNITY DETECTED PRIOR TO INTENTIONAL ALLOIMMUNIZATION.. International Journal of Immunogenetics, 1986, 13, 287-298.	1.2	7
133	Individual differences in the cytotoxic T-lymphocyte response in man to public HLA determinants. Cellular Immunology, 1986, 103, 252-271.	3.0	6
134	Natural autoreactive Hâ€²â€²-specific serum antibodies in a group of BALB/cBy (Hâ€²<sup>d</sup>) mice. Tissue Antigens, 1986, 27, 106-111.	1.0	5
135	Cross-reactions of Class II Histocompatibility Antigens of Various Species. , 1986, , 128-153.		2
136	Anti-MHC immunity detected prior to intentional alloimmunization. Immunogenetics, 1985, 21, 491-504.	2.4	12
137	BLIND CONFIRMATION OF GECZY FACTOR IN ANKYLOSING SPONDYLITIS. Lancet, The, 1985, 326, 943-944.	13.7	19
138	Frequency of naturally occurring Hâ€²â€²-specific antibodies in mouse sera monitored by â€œsuperreactiveâ€• rabbit complement. Tissue Antigens, 1985, 26, 259-261.	1.0	4
139	Activation of cytotoxic T lymphocytes in HLA-A, -B and -C-identical responder-stimulator pairs I. Tissue Antigens, 1984, 24, 81-89.	1.0	7
140	Activation of cytotoxic T lymphocytes in HLAâ€²A, â€²B and â€²Câ€²-identical responderâ€stimulator pairs II. Tissue Antigens, 1984, 24, 90-97.	1.0	13
141	A cloned cytotoxic T-lymphocyte (CTL) line recognizing a subtype of HLA B27. Human Immunology, 1984, 9, 231-242.	2.4	19
142	B27 Subtypes. , 1984, , 418-419.		4
143	Heterogeneity of HLA-B7 as Detected by Cytotoxic T Cell Clones. , 1984, , 479-480.		1
144	Biochemical analysis of variant HLA-B27 antigens. Human Immunology, 1983, 6, 111-117.	2.4	50

#	ARTICLE	IF	CITATIONS
145	Naturally occurring cytotoxic human antibodies recognize H-2-controlled murine lymphocyte antigens.. Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 4479-4483.	7.1	3
146	Allo-immune anti-H-2k <sup>k</sup> sera of individual mice detect HLA-DR-associated polymorphism on human B cells. Tissue Antigens, 1983, 22, 134-141.	1.0	1
147	A search for association of HLA antigens with paranoid schizophrenia: A9 appears as a possible marker. Tissue Antigens, 1983, 22, 186-193.	1.0	33
148	Specificity of anti-HLA-B27 cytotoxic T lymphocytes. Tissue Antigens, 1983, 22, 267-282.	1.0	20
149	Subtypes of HLA-B27 detected by cytotoxic T lymphocytes and their role in self-recognition. Human Immunology, 1982, 5, 259-268.	2.4	83
150	Natural H-2-specific antibodies in sera of aged mice. Immunogenetics, 1982, 15, 95-102.	2.4	23
151	Human Ia molecules carrying DC1 or BR4X7 determinants are not homologous to murine I-E molecules. Immunogenetics, 1982, 16, 187-199.	2.4	6
152	In vitro-isolated human cytotoxic T-lymphocyte clones detect variations in serologically defined HLA antigens. Immunogenetics, 1982, 16, 503-512.	2.4	43
153	Identification of human CML target. HLA-B locus (B12) antigen variants defined by CTL generated between B locus-identical (B12) responder-stimulator pairs. Journal of Immunology, 1982, 128, 949-55.	0.8	34
154	Fine specificity of cytotoxic T lymphocytes directed against H-2L d. Immunogenetics, 1981, 12, 75-88.	2.4	7
155	Anti-H-2 antibodies induced by syngeneic immunization. Immunogenetics, 1980, 10, 319-332.	2.4	25
156	UNEXPECTED LYMPHO-CYTOTOXIC REACTIONS OF ANTI-H-2 SERA ON NORMAL LYMPH-NODE CELLS: ARE THEY DUE TO ALTERED H-2 STRUCTURES OR ANTI-VIRAL ANTIBODIES?. International Journal of Immunogenetics, 1980, 7, 91-97.	1.2	5
157	Constancy of Cross-Reactivity Patterns in Sera of Individual Mice during the Anti-H-2 Response. Tissue Antigens, 1980, 16, 49-55.	1.0	1
158	Lymphocytotoxic antibodies produced by H-2 allo-immunisation distinguish between MuLV-positive and -negative substrains of the same H-2 haplotype. Nature, 1979, 282, 843-844.	27.8	16
159	CROSS-REACTIVITY AMONG THE PRODUCTS OF THREE NONALLELIC H-2 LOCI, H-2Ld, H-2Dq, AND H-2Kk. Transplantation, 1979, 28, 339-342.	1.0	18
160	Individual mice recognize the complex nature of H-2 antigens; unexpected reactions (anti-Kk) in anti-BALB/c-H-2d sera produced in the BALB/c-H-2db mutant. Transplantation Proceedings, 1979, 11, 642-6.	0.6	12
161	A syngeneic anti tumor serum recognizing a complex H-2 alloantigen. Immunobiology, 1979, 156, 110-20.	1.9	5
162	Anti-H-2D <sup>d</sup> Antibodies Cross-React with HLA-A11 and Aw31. Tissue Antigens, 1978, 11, 439-442.	1.0	4

#	ARTICLE	IF	CITATIONS
163	HLA ANTIGENS AS POSSIBLE MARKERS OF HETEROGENEITY IN SCHIZOPHRENIA. International Journal of Immunogenetics, 1978, 5, 165-172.	1.2	26
164	Individual mice of one inbred strain produce anti-H-2 and anti-HLA antibodies of different specificities. Tissue Antigens, 1978, 12, 32-8.	1.0	23
165	Cytotoxic Effect of Anti-H-2 and Anti-Ia Antisera on Human B and T Cells. Scandinavian Journal of Immunology, 1977, 6, 431-437.	2.7	15
166	HLA-Cw4 in Paranoid Schizophrenia. Tissue Antigens, 1977, 9, 41-44.	1.0	22
167	HLA ANTIGENS IN JUVENILE RHEUMATOID ARTHRITIS. International Journal of Immunogenetics, 1976, 3, 229-236.	1.2	7
168	HLA Antigens in Schizophrenia. Tissue Antigens, 1976, 8, 217-220.	1.0	30
169	HLA Antigens in Aged Persons. Tissue Antigens, 1975, 6, 269-271.	1.0	30
170	Relations of HLA and Rh Systems to Immune Reactivity. Vox Sanguinis, 1974, 26, 470-482.	1.5	36
171	Genetic studies on male sterility of hybrids between laboratory and wild mice (<i>Mus) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 4	0.9	198
172	Sex-Dependent and H-2-Linked Influence on Expressivity of the Brachyury Gene in Mice. Journal of Heredity, 1974, 65, 369-372.	2.4	24
173	Genetic Association between H-2 Gene and Testosterone Metabolism in Mice. Nature: New Biology, 1972, 238, 280-281.	4.5	81
174	Histocompatibility Gene Organization and Mixed Lymphocyte Reaction. Nature: New Biology, 1971, 230, 271-272.	4.5	22
175	Testosterone and testosterone binding in murine plasma. Steroidologia, 1971, 2, 113-20.	0.3	13
176	The major histocompatibility antigens in various species. Current Topics in Microbiology and Immunology, 1970, 53, 1-90.	1.1	14
177	Allo-Antigens and Antigenic Factors of Human Leukocytes. Vox Sanguinis, 1966, 11, 326-331.	1.5	19
178	Allo-Antigens and Antigenic Factors of Human Leukocytes: A Hypothesis. Vox Sanguinis, 1966, 11, 326-331.	1.5	17
179	Allo-antigens and antigenic factors of human leukocytes. A hypothesis. Vox Sanguinis, 1966, 11, 326-31.	1.5	7